The research highlights that frequent users of high-potency cannabis exhibit notable changes in genes associated with mitochondrial and immune functions, especially the CAVIN1 gene.

Focusing on THC concentrations of 10% or more, the study examined the impact on DNA, specifically in genes related to energy and immune system functions.

Researchers analyzed DNA methylation in blood samples from a total of 682 participants, including those with first-episode psychosis and healthy controls.

The study involved 239 participants who had their first psychotic episode and 443 healthy volunteers from the UK, France, and Spain, with 38 percent using cannabis more than once a week, primarily high-potency varieties.

Senior author Professor Marta Di Forti emphasized the necessity of understanding cannabis's biological effects, particularly in relation to mental health.

The participant demographics revealed an average first use of cannabis at 16 years old, with most individuals consuming high-potency cannabis more than once a week.

The study found that daily users of high-potency cannabis are five times more likely to develop psychosis than non-users, with symptoms such as hallucinations and paranoia.

Notably, the findings were distinct from the effects of tobacco, which many cannabis users often mix with their cannabis.

The results illustrate how external factors like drug use can influence gene function, underscoring the need for prevention strategies for psychotic disorders amid the rising use of high-potency cannabis.

Overall, the study focused on DNA methylation, a process that modifies gene functionality without altering the DNA sequence, linking environmental factors like cannabis use to mental health outcomes.

A recent study published in Molecular Psychiatry reveals that regular use of high-potency cannabis significantly alters DNA patterns, particularly among individuals who have experienced psychosis.

Conducted by the Genetic and Psychosis study team in south London and the EU-GEI study, the research was funded by the Medical Research Council and the NIHR Maudsley and Exeter Biomedical Research Centres.